Fatigue independently predicts different work disability dimensions in etanercept-treated RA and AS patients

Katie Druce, Laraine Aikman, Maria Dilleen, Annie Burden, Piotr Szczypa, Neil Basu

Research output: Contribution to journalArticle

1 Citation (Scopus)
3 Downloads (Pure)

Abstract

Background: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept.

Methods: Two observational studies, comprising RA and AS etanercept commencers respectively, were analysed. Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12 months) and the interaction between visit and each of the explanatory variables.

Results: A total of 1003 AS, and 1747 RA, patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient: 3.75, 95% CI 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model OR: 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient: 3.44, 95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85) and absenteeism (OR: 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time.

Conclusions: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on the absenteeism, presenteeism, productivity loss and activity impairment of RA patients and a significant but dimension selective effect on work disability among AS patients.

ClinicalTrials.gov Trial Registration: NCT00544557: 16/10/2007, NCT00488475: 20/06/2006
Original languageEnglish
Article number96
JournalArthritis Research & Therapy
Volume20
DOIs
Publication statusPublished - 29 May 2018

Fingerprint

Ankylosing Spondylitis
Fatigue
Rheumatoid Arthritis
Absenteeism
Efficiency
Linear Models
Biological Therapy
Etanercept
Observational Studies

Keywords

  • fatigue
  • work disability
  • rheumatoid arthritis
  • spondyloarthritis

Cite this

Fatigue independently predicts different work disability dimensions in etanercept-treated RA and AS patients. / Druce, Katie; Aikman, Laraine; Dilleen, Maria; Burden, Annie; Szczypa, Piotr; Basu, Neil.

In: Arthritis Research & Therapy, Vol. 20, 96, 29.05.2018.

Research output: Contribution to journalArticle

Druce, Katie ; Aikman, Laraine ; Dilleen, Maria ; Burden, Annie ; Szczypa, Piotr ; Basu, Neil. / Fatigue independently predicts different work disability dimensions in etanercept-treated RA and AS patients. In: Arthritis Research & Therapy. 2018 ; Vol. 20.
@article{c4406b4743d64cfba1ccf7726a99617c,
title = "Fatigue independently predicts different work disability dimensions in etanercept-treated RA and AS patients",
abstract = "Background: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept.Methods: Two observational studies, comprising RA and AS etanercept commencers respectively, were analysed. Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12 months) and the interaction between visit and each of the explanatory variables.Results: A total of 1003 AS, and 1747 RA, patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient: 3.75, 95{\%} CI 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model OR: 1.18, 95{\%} CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient: 3.44, 95{\%} CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85) and absenteeism (OR: 1.23, 95{\%} CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time.Conclusions: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on the absenteeism, presenteeism, productivity loss and activity impairment of RA patients and a significant but dimension selective effect on work disability among AS patients.ClinicalTrials.gov Trial Registration: NCT00544557: 16/10/2007, NCT00488475: 20/06/2006",
keywords = "fatigue, work disability, rheumatoid arthritis, spondyloarthritis",
author = "Katie Druce and Laraine Aikman and Maria Dilleen and Annie Burden and Piotr Szczypa and Neil Basu",
note = "Funding: This study was supported by Pfizer. The sponsor was involved in the study design, collection, analysis and interpretation of data as well as revising the manuscript for intellectual content.",
year = "2018",
month = "5",
day = "29",
doi = "10.1186/s13075-018-1598-8",
language = "English",
volume = "20",
journal = "Arthritis Research & Therapy",
issn = "1478-6354",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Fatigue independently predicts different work disability dimensions in etanercept-treated RA and AS patients

AU - Druce, Katie

AU - Aikman, Laraine

AU - Dilleen, Maria

AU - Burden, Annie

AU - Szczypa, Piotr

AU - Basu, Neil

N1 - Funding: This study was supported by Pfizer. The sponsor was involved in the study design, collection, analysis and interpretation of data as well as revising the manuscript for intellectual content.

PY - 2018/5/29

Y1 - 2018/5/29

N2 - Background: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept.Methods: Two observational studies, comprising RA and AS etanercept commencers respectively, were analysed. Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12 months) and the interaction between visit and each of the explanatory variables.Results: A total of 1003 AS, and 1747 RA, patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient: 3.75, 95% CI 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model OR: 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient: 3.44, 95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85) and absenteeism (OR: 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time.Conclusions: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on the absenteeism, presenteeism, productivity loss and activity impairment of RA patients and a significant but dimension selective effect on work disability among AS patients.ClinicalTrials.gov Trial Registration: NCT00544557: 16/10/2007, NCT00488475: 20/06/2006

AB - Background: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept.Methods: Two observational studies, comprising RA and AS etanercept commencers respectively, were analysed. Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12 months) and the interaction between visit and each of the explanatory variables.Results: A total of 1003 AS, and 1747 RA, patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient: 3.75, 95% CI 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model OR: 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient: 3.44, 95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85) and absenteeism (OR: 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time.Conclusions: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on the absenteeism, presenteeism, productivity loss and activity impairment of RA patients and a significant but dimension selective effect on work disability among AS patients.ClinicalTrials.gov Trial Registration: NCT00544557: 16/10/2007, NCT00488475: 20/06/2006

KW - fatigue

KW - work disability

KW - rheumatoid arthritis

KW - spondyloarthritis

U2 - 10.1186/s13075-018-1598-8

DO - 10.1186/s13075-018-1598-8

M3 - Article

VL - 20

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

SN - 1478-6354

M1 - 96

ER -